<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37088550</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1347-7439</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of veterinary medical science</Title><ISOAbbreviation>J Vet Med Sci</ISOAbbreviation></Journal><ArticleTitle>Relationship between neutrophil gelatinase-associated lipocalin levels and disease parameters including clinicopathological parameters and various cytokine levels in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>601</StartPage><EndPage>608</EndPage><MedlinePgn>601-608</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1292/jvms.23-0015</ELocationID><Abstract><AbstractText>Urine neutrophil gelatinase-associated lipocalin (NGAL) is a marker of acute kidney injury and indicates tubular damage. Lupus nephritis-associated renal injury is characterized by damage to the glomeruli and tubular portions of the kidneys. Therefore, NGAL concentrations are expected to vary according to the severity of systemic lupus erythematosus (SLE). In this study, samples from (NZB &#xd7; NZW) F1 mice at an advanced stage of SLE were used to determine whether serum and urine NGAL concentrations or the urine NGAL:creatinine (uNGAL/C) ratio can be used to reflect diet, disease state, and treatment efficacy. Additionally, the relationship between the levels of NGAL and various cytokines in the serum in SLE was evaluated. Mice were divided into the following four groups (n=15): CN, chow diet and no treatment (saline; intraperitonially injected [i.p.]; 200 &#x3bc;L/day); CP, chow diet and methylprednisolone (i.p.; 5 mg/kg/day); HN, high-fat diet and no treatment (saline [i.p.]; 200 &#x3bc;L/day); and HP, high-fat diet and methylprednisolone treatment (i.p.; 5 mg/kg/day) every day from 6 to 42 weeks of age. The serum and urine NGAL levels and uNGAL/C values were significantly lower in the CP group than those in the CN group. Further, serum NGAL concentration demonstrated a strong positive correlation with urine NGAL levels, uNGAL/C, urine protein concentrations, urine protein:creatinine ratio, and the expression of several cytokines associated with SLE pathogenesis (interleukin [IL]-6, tumor necrosis factor [TNF]-&#x3b1;, and interferon-induced protein [IP]-10). These results suggest that NGAL has a strong positive correlation with the clinicopathological parameters and several key cytokines in SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Eun Wha</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Department of Veterinary Clinical Pathology, College of Veterinary Medicine &amp; Institute of Veterinary Science, Kangwon National University, Gangwon-do, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Vet Med Sci</MedlineTA><NlmUniqueID>9105360</NlmUniqueID><ISSNLinking>0916-7250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071068">Lipocalin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000209">Acute-Phase Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054834">Lipocalins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber><NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071068" MajorTopicYN="N">Lipocalin-2</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000209" MajorTopicYN="N">Acute-Phase Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054834" MajorTopicYN="N">Lipocalins</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012376" MajorTopicYN="Y">Rodent Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(NZB&#xd7;NZW) F1 mice</Keyword><Keyword MajorTopicYN="N">cytokine</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">neutrophil gelatinase-associated lipocalin</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The author declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>23</Day><Hour>21</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37088550</ArticleId><ArticleId IdType="pmc">PMC10315541</ArticleId><ArticleId IdType="doi">10.1292/jvms.23-0015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aringer M, Smolen JS. 2005. Cytokine expression in lupus kidneys. Lupus 14: 13&#x2013;18. doi: 10.1191/0961203305lu2053oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203305lu2053oa</ArticleId><ArticleId IdType="pubmed">15732282</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JF, Morales M, Qatanani M, Cucchiara A, Nackos E, Lazar MA, Teff K, von Feldt JM. 2011. Resistin levels in lupus and associations with disease-specific measures, insulin resistance, and coronary calcification. J Rheumatol 38: 2369&#x2013;2375. doi: 10.3899/jrheum.110237</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.110237</ArticleId><ArticleId IdType="pmc">PMC5702914</ArticleId><ArticleId IdType="pubmed">21885493</ArticleId></ArticleIdList></Reference><Reference><Citation>Belmont HM, Abramson SB, Lie JT. 1996. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 39: 9&#x2013;22. doi: 10.1002/art.1780390103</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390103</ArticleId><ArticleId IdType="pubmed">8546744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M. 2009. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4: 337&#x2013;344. doi: 10.2215/CJN.03530708</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03530708</ArticleId><ArticleId IdType="pmc">PMC2637601</ArticleId><ArticleId IdType="pubmed">19176795</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, Buemi M. 2009. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 32: 91&#x2013;98. doi: 10.1159/000209379</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000209379</ArticleId><ArticleId IdType="pubmed">19321980</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanella GS, Luster AD. 2009. Chapter 18. A chemokine-mediated in vivo T-cell recruitment assay. Methods Enzymol 461: 397&#x2013;412. doi: 10.1016/S0076-6879(09)05418-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(09)05418-4</ArticleId><ArticleId IdType="pmc">PMC3855672</ArticleId><ArticleId IdType="pubmed">19480929</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A. 2010. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 37: 60&#x2013;70. doi: 10.3899/jrheum.090194</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090194</ArticleId><ArticleId IdType="pubmed">19955044</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi EW, Kim HJ, Jung YC, Go HS, Seong JK. 2022. Effects of high fat diet-induced obesity on pathophysiology, immune cells, and therapeutic efficacy in systemic lupus erythematosus. Sci Rep 12: 18532. doi: 10.1038/s41598-022-21381-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-21381-3</ArticleId><ArticleId IdType="pmc">PMC9630451</ArticleId><ArticleId IdType="pubmed">36323742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H, He Y, Li K, Yang J, Li X, Lu R, Gao W. 2007. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 123: 227&#x2013;234. doi: 10.1016/j.clim.2007.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2007.01.010</ArticleId><ArticleId IdType="pubmed">17360238</ArticleId></ArticleIdList></Reference><Reference><Citation>Enderlin M, Kleinmann EV, Struyf S, Buracchi C, Vecchi A, Kinscherf R, Kiessling F, Paschek S, Sozzani S, Rommelaere J, Cornelis JJ, Van Damme J, Dinsart C. 2009. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 16: 149&#x2013;160. doi: 10.1038/cgt.2008.62</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2008.62</ArticleId><ArticleId IdType="pubmed">18670452</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournel C, Chabanne L, Caux C, Faure JR, Rigal D, Magnol JP, Monier JC. 1992. Canine systemic lupus erythematosus. I: A study of 75 cases. Lupus 1: 133&#x2013;139. doi: 10.1177/096120339200100303</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339200100303</ArticleId><ArticleId IdType="pubmed">1301973</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2015 Disease Injury Incidence Prevalence Collaborators. 2016. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990&#x2013;2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388: 1545&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055577</ArticleId><ArticleId IdType="pubmed">27733282</ArticleId></ArticleIdList></Reference><Reference><Citation>Groom JR, Luster AD. 2011. CXCR3 in T cell function. Exp Cell Res 317: 620&#x2013;631. doi: 10.1016/j.yexcr.2010.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2010.12.017</ArticleId><ArticleId IdType="pmc">PMC3065205</ArticleId><ArticleId IdType="pubmed">21376175</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson GK, Hermansson A. 2011. The immune system in atherosclerosis. Nat Immunol 12: 204&#x2013;212. doi: 10.1038/ni.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2001</ArticleId><ArticleId IdType="pubmed">21321594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara K, Hirano T. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13: 357&#x2013;368. doi: 10.1016/S1359-6101(02)00027-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6101(02)00027-8</ArticleId><ArticleId IdType="pubmed">12220549</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson L, Linn&#xe9;r A, Sund&#xe9;n-Cullberg J, Haggar A, Herwald H, Lor&#xe9; K, Treutiger CJ, Norrby-Teglund A. 2009. Neutrophil-derived hyperresistinemia in severe acute streptococcal infections. J Immunol 183: 4047&#x2013;4054. doi: 10.4049/jimmunol.0901541</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901541</ArticleId><ArticleId IdType="pubmed">19717514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaucs&#xe1;r T, God&#xf3; M, R&#xe9;v&#xe9;sz C, Kov&#xe1;cs M, M&#xf3;csai A, Kiss N, Albert M, Kren&#xe1;cs T, Sz&#xe9;n&#xe1;si G, Hamar P. 2016. Urine/plasma neutrophil gelatinase associated lipocalin ratio is a sensitive and specific marker of subclinical acute kidney injury in mice. PLoS One 11: e0148043. doi: 10.1371/journal.pone.0148043</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0148043</ArticleId><ArticleId IdType="pmc">PMC4732663</ArticleId><ArticleId IdType="pubmed">26824608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern L, Mittenb&#xfc;hler MJ, Vesting AJ, Ostermann AL, Wunderlich CM, Wunderlich FT. 2018. Obesity-induced TNF&#x3b1; and IL-6 signaling: the missing link between obesity and inflammation-driven liver and colorectal cancers. Cancers (Basel) 11: E24. doi: 10.3390/cancers11010024</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11010024</ArticleId><ArticleId IdType="pmc">PMC6356226</ArticleId><ArticleId IdType="pubmed">30591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong KO, Tan AW, Thong BYH, Lian TY, Cheng YK, Teh CL, Koh ET, Chng HH, Law WG, Lau TC, Leong KP, Leung BP, Howe HS. 2009. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 156: 134&#x2013;140. doi: 10.1111/j.1365-2249.2009.03880.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2009.03880.x</ArticleId><ArticleId IdType="pmc">PMC2673751</ArticleId><ArticleId IdType="pubmed">19175619</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, Stiles JK. 2011. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22: 121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203691</ArticleId><ArticleId IdType="pubmed">21802343</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon M, Skaggs B. 2014. Pathogenesis and treatment of atherosclerosis in lupus. Rheum Dis Clin North Am 40: 475&#x2013;495, viii. doi: 10.1016/j.rdc.2014.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2014.04.003</ArticleId><ArticleId IdType="pmc">PMC6152881</ArticleId><ArticleId IdType="pubmed">25034157</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B. Lupus Interferon Skin Activity (LISA) Study Investigators.2011. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon &#x3b1; monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 70: 1905&#x2013;1913. doi: 10.1136/ard.2010.144485</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.144485</ArticleId><ArticleId IdType="pubmed">21798883</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakhjavani MRJ, Abediazar S, Ghorbanihaghjo A, Hanafizadeh B, Vahed SZ, Pourlak T. 2019. The importance of serum neutrophil gelatinase-associated lipocalin level in patients with lupus nephritis. J Renal Inj Prev 8: 133&#x2013;139. doi: 10.15171/jrip.2019.25</Citation><ArticleIdList><ArticleId IdType="doi">10.15171/jrip.2019.25</ArticleId></ArticleIdList></Reference><Reference><Citation>Narumi S, Takeuchi T, Kobayashi Y, Konishi K. 2000. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine 12: 1561&#x2013;1565. doi: 10.1006/cyto.2000.0757</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2000.0757</ArticleId><ArticleId IdType="pubmed">11023674</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijjar JS, Smith KGC. 2020. Systemic lupus erythematosus. pp. 555&#x2013;573. In: The Autoimmune Diseases, 6th ed. (Rose NR, Mackay IR eds.), Academic Press, Massachusetts.</Citation></Reference><Reference><Citation>R&#xf6;nnblom L, Alm GV, Eloranta ML. 2011. The type I interferon system in the development of lupus. Semin Immunol 23: 113&#x2013;121. doi: 10.1016/j.smim.2011.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2011.01.009</ArticleId><ArticleId IdType="pubmed">21292501</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose T, Gr&#xfc;tzkau A, Hirseland H, Huscher D, D&#xe4;hnrich C, Dzionek A, Ozimkowski T, Schlumberger W, Enghard P, Radbruch A, Riemekasten G, Burmester GR, Hiepe F, Biesen R. 2013. IFN&#x3b1; and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 72: 1639&#x2013;1645. doi: 10.1136/annrheumdis-2012-201586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201586</ArticleId><ArticleId IdType="pubmed">23117242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rybi-Szumi&#x144;ska A, Wasilewska A, Litwin M, Ku&#x142;aga Z, Szumi&#x144;ski M. 2013. Paediatric normative data for urine NGAL/creatinine ratio. Acta Paediatr 102: e269&#x2013;e272. doi: 10.1111/apa.12200</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.12200</ArticleId><ArticleId IdType="pubmed">23419019</ArticleId></ArticleIdList></Reference><Reference><Citation>Segerer S, Cui Y, Hudkins KL, Goodpaster T, Eitner F, Mack M, Schl&#xf6;ndorff D, Alpers CE. 2000. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis. J Am Soc Nephrol 11: 2231&#x2013;2242. doi: 10.1681/ASN.V11122231</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V11122231</ArticleId><ArticleId IdType="pubmed">11095646</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. 2016. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315: 801&#x2013;810. doi: 10.1001/jama.2016.0287</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. 2001. The hormone resistin links obesity to diabetes. Nature 409: 307&#x2013;312. doi: 10.1038/35053000</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35053000</ArticleId><ArticleId IdType="pubmed">11201732</ArticleId></ArticleIdList></Reference><Reference><Citation>Studnicka-Benke A, Steiner G, Petera P, Smolen JS. 1996. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35: 1067&#x2013;1074. doi: 10.1093/rheumatology/35.11.1067</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/35.11.1067</ArticleId><ArticleId IdType="pubmed">8948291</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi SK, Barbhaiya M, Malspeis S, Lu B, Sparks JA, Karlson EW, Willett W, Costenbader KH. 2017. Obesity and the risk of systemic lupus erythematosus among women in the Nurses&#x2019; Health Studies. Semin Arthritis Rheum 47: 376&#x2013;383. doi: 10.1016/j.semarthrit.2017.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2017.05.011</ArticleId><ArticleId IdType="pmc">PMC5675759</ArticleId><ArticleId IdType="pubmed">28688713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. 2016. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12: 716&#x2013;730. doi: 10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, Li SH, Wang CH, Fedak PWM, Li RK, Weisel RD, Mickle DAG. 2003. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108: 736&#x2013;740. doi: 10.1161/01.CIR.0000084503.91330.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000084503.91330.49</ArticleId><ArticleId IdType="pubmed">12874180</ArticleId></ArticleIdList></Reference><Reference><Citation>Vissers MCM, Fantone JC, Wiggins R, Kunkel SL. 1989. Glomerular basement membrane-containing immune complexes stimulate tumor necrosis factor and interleukin-1 production by human monocytes. Am J Pathol 134: 1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1879566</ArticleId><ArticleId IdType="pubmed">2783637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. 1996. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 93: 8563&#x2013;8568. doi: 10.1073/pnas.93.16.8563</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.16.8563</ArticleId><ArticleId IdType="pmc">PMC38712</ArticleId><ArticleId IdType="pubmed">8710910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoja C, Liu XH, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong QG, Rollins BJ, Bertani T, Remuzzi G. 1997. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 8: 720&#x2013;729. doi: 10.1681/ASN.V85720</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V85720</ArticleId><ArticleId IdType="pubmed">9176841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>